Despite the controversy surrounding the design of the Tackling EArly Morbidity and Mortality in Myeloma (TEAMM) trial (ISRCTN51731976), a Phase III randomized study that assessed the benefit of antibiotic prophylaxis and its effect on healthcare-associated infections in patients with multiple myeloma (MM), follow-up results have shown that patients do benefit from the therapy. Here, Martin Kaiser, MD, of The Royal Marsden Hospital NHS Foundation Trust, London, UK, shares his thoughts on the trial, which was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
ASH highlights: groundbreaking results from the TEAMM trial
